Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on June 1, 2008

Papers In Press, published online ahead of print February 26, 2008
J. Lipid Res., doi:10.1194/jlr.M700481-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M700481-JLR200v1
49/6/1254    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burgess, B. L.
Right arrow Articles by Wellington, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burgess, B. L.
Right arrow Articles by Wellington, C. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on October 23, 2007
Revised on February 25, 2008
Accepted on February 25, 2008

ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo

Braydon L. Burgess, Pamela F. Parkinson, Margaret M. Racke, Veronica Hirsch-Reinshagen, Jianjia Fan, Charmaine Wong, Sophie Stukas, Louise Theroux, Jeniffer Y. Chan, James Donkin, Anna Wilkinson, Danielle Balik, Brian Christie, Judes Poirier, Dieter Lutjohann, Ronald B. DeMattos, and Cheryl L. Wellington

University of British Columbia, Vancouver, British Columbia V6z 4H4

Corresponding Author: cheryl{at}cmmt.ubc.ca

Cholesterol biosynthesis has a complex relationship with the pathogenesis of Alzheimer’s Disease (AD), and genes that regulate cholesterol homeostasis are of potential therapeutic importance for this devastating disease. Genes that respond to LXR agonists are of particular interest, as synthetic liver-X-receptor (LXR) agonists decrease neuropathological and cognitive phenotypes in AD mouse models, whereas LXRa/ß deficient mice exhibit increased Aß and amyloid deposition. The cholesterol transporter ABCG1 is highly expressed in brain and responds to LXR stimulation. In vitro, conflicting reports exist as to whether ABCG1 promotes or impedes Aß production and secretion from APP-expressing cells. To clarify the in vivo roles of selective ABCG1 overexpression in Aß metabolism and brain cholesterol homeostasis, we assessed neuropathological and cognitive outcome measures in PDAPP mice expressing excess ABCG1. We observed that a 6-fold increase in ABCG1 levels did not alter Aß, amyloid, apoE levels, or cholesterol efflux, nor did it alter cognitive performance. Furthermore, endogenous murine Aß levels were not robustly changed in either ABCG1-overexpressing or in ABCG1-deficient mice. These data argue against a direct role for ABCG1 in AD. However, ABCG1 does affect brain sterol homeostasis in vivo. Excess ABCG1 is associated with decreased levels of sterol precursors and increased levels of SREBP-2 and HMGCoA-R mRNA, whereas deficiency of ABCG1 leads to the opposite effects. Although functions for ABCG1 in cholesterol efflux and Aß metabolism have been proposed based on results with cellular model systems, the in vivo role of this enigmatic transporter is largely one of regulating the sterol biosynthetic pathway.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement